Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2002 13
2003 12
2004 12
2005 18
2006 24
2007 25
2008 34
2009 27
2010 42
2011 45
2012 50
2013 44
2014 47
2015 51
2016 64
2017 47
2018 51
2019 78
2020 92
2021 90
2022 114
2023 84
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

985 results

Results by year

Filters applied: . Clear all
Page 1
Directed cell migration towards softer environments.
Isomursu A, Park KY, Hou J, Cheng B, Mathieu M, Shamsan GA, Fuller B, Kasim J, Mahmoodi MM, Lu TJ, Genin GM, Xu F, Lin M, Distefano MD, Ivaska J, Odde DJ. Isomursu A, et al. Among authors: lin m. Nat Mater. 2022 Sep;21(9):1081-1090. doi: 10.1038/s41563-022-01294-2. Epub 2022 Jul 11. Nat Mater. 2022. PMID: 35817964 Free PMC article.
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P. Heerspink HJL, et al. Among authors: lin m. Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931629 Clinical Trial.
Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial.
Liu X, Dai Q, Ye R, Zi W, Liu Y, Wang H, Zhu W, Ma M, Yin Q, Li M, Fan X, Sun W, Han Y, Lv Q, Liu R, Yang D, Shi Z, Zheng D, Deng X, Wan Y, Wang Z, Geng Y, Chen X, Zhou Z, Liao G, Jin P, Liu Y, Liu X, Zhang M, Zhou F, Shi H, Zhang Y, Guo F, Yin C, Niu G, Zhang M, Cai X, Zhu Q, Chen Z, Liang Y, Li B, Lin M, Wang W, Xu H, Fu X, Liu W, Tian X, Gong Z, Shi H, Wang C, Lv P, Tao Z, Zhu L, Yang S, Hu W, Jiang P, Liebeskind DS, Pereira VM, Leung T, Yan B, Davis S, Xu G, Nogueira RG; BEST Trial Investigators. Liu X, et al. Among authors: lin m. Lancet Neurol. 2020 Feb;19(2):115-122. doi: 10.1016/S1474-4422(19)30395-3. Epub 2019 Dec 9. Lancet Neurol. 2020. PMID: 31831388 Clinical Trial.
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Heerspink HJL, Greasley PJ, Ahlström C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnåker M, Turton M, Wheeler DC, Ambery P. Heerspink HJL, et al. Among authors: lin m. Nephrol Dial Transplant. 2024 Feb 28;39(3):414-425. doi: 10.1093/ndt/gfad183. Nephrol Dial Transplant. 2024. PMID: 37632201 Free PMC article. Clinical Trial.
Emerging role of FBXO22 in carcinogenesis.
Cheng J, Lin M, Chu M, Gong L, Bi Y, Zhao Y. Cheng J, et al. Among authors: lin m. Cell Death Discov. 2020 Jul 27;6:66. doi: 10.1038/s41420-020-00303-0. eCollection 2020. Cell Death Discov. 2020. PMID: 32793396 Free PMC article. Review.
Cellular mechanosensing of texture features.
Lin M. Lin M. Biophys J. 2022 Dec 6;121(23):4417-4418. doi: 10.1016/j.bpj.2022.10.028. Epub 2022 Oct 21. Biophys J. 2022. PMID: 36323310 Free PMC article. No abstract available.
Optical neural ordinary differential equations.
Zhao Y, Chen H, Lin M, Zhang H, Yan T, Huang R, Lin X, Dai Q. Zhao Y, et al. Among authors: lin m. Opt Lett. 2023 Feb 1;48(3):628-631. doi: 10.1364/OL.477713. Opt Lett. 2023. PMID: 36723549
985 results